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 Hydrophilic pore formers in nano range was prepared using ball mill 
 Pore former concentration in the coating had crucial effect on coating integrity 
 Gelling agent concentration in the coating had crucial effect on coating integrity 













In controlled porosity osmotic pumps (CPOP), usually finding a single solvent with a capability to 
dissolve both film former (hydrophobic) and pore former (hydrophilic) is extremely challenging. 
Therefore, the aim of the present investigation was to tackle the issue associated with controlled 
porosity osmotic pump (CPOP) system using nano-suspension coating method. In the present study 
4-Amino pyridine was used as a highly water soluble drug. In this method, a hydrophilic pore former 
(sucrose or mannitol) in nano range was suspended in polymeric coating solution using ball-mill. The 
performance of the prepared formulations was assessed in terms of D12h (cumulative release percent after 
12 hours), Devzero (mean percent deviation of drug release from zero order kinetic), tL (lag time of the 
drug release) and RSQzero. The results revealed that gelling agent amount (HPMC E15LV) in core and pore 
former concentration in SPM had crucial effect on SPM integrity. All the optimised formulations 
showed a burst drug release due to fast dissolving nature of the pore formers. Results obtained from 
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scanning electron microscopy demonstrated the formation of nanopores in the membrane where the drug 
release takes place via these nanopores. Nano suspension coating method can be introduced as novel 
method in formulation of CPOPs. 
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In recent years, novel drug delivery systems (NDDS) have gained great attention due to providing 
sustained and constant drug release. Among NDDS, per oral controlled release (CR) systems including 
matrices, reservoirs and osmotic devices allocated the foremost market segment because of their 
advantages over others delivery systems [1]. On the other hand, the drug release from other delivery 
systems can be affected by the presence of food, pH and other physiological factors. The independency of 
these factors to a large extent in the case of osmotic systems is considered as advantages [2, 3]. 
Osmotic pumps devices can be very useful for delivery of drugs, particularly for drugs with short 
biological half-life which requires frequent consumption during 24 hours [4]. Many different systems 
have been developed based on the principle of osmotic pressure and some of these systems have reached 
the market.  Elementary osmotic pump (EOP) [5-7], sandwiched osmotic tablet system (SOTS) [8], push-
pull systems (PPOP) [9-12], controlled porosity osmotic pumps (CPOP) [13, 14], tablet in tablet (TNT) 
cores [15], Asymmetric membrane capsule for osmotic drug delivery [12, 16], osmotic systems made by 
swellable-core technology [17] and swellable elementary osmotic pump(SEOP) [18, 19]  can be noted. 
An EOP device principally consists of an osmotically active core covered by a semipermeable membrane 
(SPM) generally composed of cellulose acetate as film former and a small orifice drilled by laser beam or 
4 
 
mechanical drills [2, 20]. Controlled porosity osmotic pumps (CPOPs) are very simple forms of osmotic 
systems which the delivery orifice is formed by the incorporation of a water-soluble component in the 
membrane [21, 22]. Thus, there is no need for sophisticated equipment for drilling of SPM. Other 
advantages of this system over EOPs are the drug release occurs from the entire surface of the membrane 
consequently decreasing the chance of pore-blocking which generally leads to release stop or system 
cracking. Once the tablet exposes to the aqueous media, the hydrophilic component dissolves and 
produces microscopic holes in SPM for release of drug solution [23, 24]. The main polymer in (CPOP) 
construction is a hydrophobic polymer to form a semi-permeable membrane which is completely 
insoluble in water such as cellulose acetate or cellulose acetate butyrate [25].  Liquid coating (solvent 
system) should be an organic solvent such as acetone with low polarity or a combination of non-polar 
solvents in order to solve this polymer [23]. Due to the very low water solubility of these polymers even a 
small amount of water in the composition of the coating liquid cannot be used. The other main ingredients 
used in the formulation of semi-permeable membrane for this kind of osmotic systems are pore formers 
that after exposing the tablet to aqueous solutions (dissolution medium) can produce pores to release the 
drug [24]. Therefore, these materials should have high water solubility leading to the drug release in 
aqueous media instantly. 
Technical problem in the preparation of these tablets is simultaneously dissolving lipophilic film former 
and hydrophilic pore formers in one solvent system. Using highly water soluble materials as pore formers 
in the SPM composition can result in reduction of the lag time of drug release from CPOP systems and 
increasing amount of released drug from CPOPs. Since the used pore formers with high solubility in 
water have a low solubility in acetone-ethanol solvent thus in the present study an attempt was made to 
employ nano-sized pore former solid particles suspended in a polymer solution to tackle the release issue.  
The micro-sized pore former particles suspended in polymeric solution has already been applied in our 
research lab [26], but in the present study, the authors have focused on employing nano-sized pore former 




2. Materials and Methods 
2.1 Materials 
4-Amino pyridine (purity >99%) was obtained from Merck Chemicals (Germany).  Cellulose acetate 
with 40 % acetyl groups (Fluka, Switzerland) was used as film former polymer (SPM). Hydroxypropyl 
methylcellulose (HPMC E15LV) (Colorcon, England) was used as water-swellable polymer and gelling 
agent. Polyethylene glycol (PEG) 200 (Pharmaceutical grad) and castor oil (Pharmaceutical grade; 
Merck, Germany) were used as plasticizer. Avicel PH101 (Blanver, Korea) was used as compressibility 
enhancer. Other material such as acetone (HPLC grade), absolute ethanol (HPLC grade), talc (purity 
98%) and lactose monohydrate (Pharmaceutical grade) were purchased from Merck Company 
(Germany). Sucrose and mannitol (Pharmaceutical grade; Merck, Germany) were used as a solid pore 
former in formulation of SPM with different percentages. Sucrose was applied as osmotically active agent 
in core tablet formulation. 
 
2.2 Preparation of core tablets of osmotic systems 
4-Amino pyridine powder was micronized by jet mill (Fritsch FE80N, Germany) before using in tableting 
process. Drug powders along with other core ingredients were mixed thoroughly for 10 min by mortar 
and pestle. Then the mixture was compressed into biconvex tablets using a single tablet press (Korsch, 
Germany) with 9 mm diameter oval biconvex punches. The final weight of each tablet was kept at 465 
mg in order to have a similar volume and surface area for the tablets. All of the core formulations 





2.3 Coating of core tablets 
The prepared core tablets were coated with a coating suspension containing cellulose acetate, castor oil, 
PEG200 and nano-suspended sucrose or mannitol in acetone/ethanol mixture (90:10) employing dip 
coating technique. In this technique, the cores were fixed with micro-drill (micro drill diameter was 
around 350 µm and held by a hand piece) and floated into coating suspension for 5 seconds with a 
gentle horizontal rotation and drying at room temperature. This step was repeated several times until the 
intended membrane thickness (125 ± 10 μm) was achieved. Micro-drills were pulled out from the 
coated tablets by rotating hand piece and the created micro pore was sealed by small amount of 
coating solution. The same condition was maintained during coating of all tablets and thickness of 
membrane was periodically checked using digital micrometer (Mitotoyo, Japan) with high accuracy 
(0.001 mm). Cellulose acetate (6 g) and plasticizers namely, castor oil (3 %w/v), and PEG200 (2 %w/v) 
were dissolved in 100 ml of coating liquid. Due to poor solubility of sucrose in this solvent mixture and 
preparing nano-suspension, the sucrose particles was suspended in the acetone/ethanol mixture (90:10 
v/v) inside the ball-mill chamber (Retsch® PM100, Germany). The volume of the chamber was 25 ml 
containing 8 balls with 10 mm diameter. The sample was ground for 3 hours at 350 rpm, and at 10 min 
intervals a diverse rotation was applied.  
During dip coating process the coating suspension was continuously stirred to maintain a good uniformity 
while using in the process. The core and SPM compositions for different formulations are presented in 
Table 1. 
 
2.4 Particle Size Analyzing 
The particle size of sucrose and mannitol particles suspended in acetone/ethanol mixture after grinding in 




2.5 Scanning electron microscopy (SEM) 
SEM images were prepared from selected and blank formulations using Tescan (Czech 
Republic) apparatus with different magnifications after exposing the tablets to the aqueous media 
in order to assess the size and shape of pores formed by dissolving the pore formers in SPM 
structure. Prior to assessment with acceleration voltage of 15.0 kV, the samples were prepared 
on aluminum stubs and coated with gold using sputter gold coating method. 
 
2.6 In vitro release test 
In vitro release studies were carried out using a dissolution apparatus II paddle method (Erweka DT-6 R, 
Germany), set at 100 rpm (rotating speed) and 900 mL distilled water maintained at 37 ± 0.1°C. At 
different time intervals (5, 10, 15, 45 minutes and 1, 1/5, 2, 4, 6, 8, 10, 12, and 24 h) 5 ml of the 
dissolution medium were withdrawn and analyzed spectrophotometrically (UV spectrophotometer, 
Shimadzu Mini 1240, Japan) at 260.8 nm. The withdrawn dissolution medium was instantly replaced by 
the same volume of the fresh medium. The release test was performed at least for 3 tablets and the 
corresponding mean and standard deviations (SD) were calculated. 
2.7 Mathematical treatments 
The release profile of a perfect osmotic system should follow zero order kinetics for a period of at least 12 
h with a majority of drug should be release within this period. Formulations with acceptable stability and 
release pattern were selected for further evaluations. As an ideal osmotic system should possess the ability 
to release a high percentage of drug content with a constant release rate (zero order kinetics) in the period 
of 12 h with low lag time, therefore, comparative parameters including D12h  (percent of the drug released 
within 12), tL (lag time of the drug release from device), RSQzero (R square of release data fitted to zero 
order equation) and Devzero (mean percentage deviation of the release data from zero order release), were 
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calculated to evaluate the performance of the formulations. Lag time defines as time required to reach 
steady state drug release from osmotic devices. Devzero was calculated based on: 
Devzero (%) =100/N∑〖(Qcalc-Qobs)/Qobs〗 
Where Qobs is the value of measured amount of drug released in each sampling time, Qcalc is the calculated 
amount of the drug released according to zero order equation for the same time and N is the number of 
sampling times. 
 
3. Results and Discussion   
3.1 Particle size analyzing 
Figure 1 demonstrated the particle size distribution of prepared the nano-suspended sucrose and mannitol 
particles. The results showed that the mean volume diameters of nano-sized sucrose and mannitol were 
476 and 511 nm respectively. This was in a good agreement with the size of pore generated after the 
dissolution of SPM as confirmed by SEM and discussed below. 
  
3.2 Scanning electron microscopy (SEM) 
SEM images from SPM were obtained after 12 h exposure to the dissolution medium. Based on Figure 2, 
the nano-pores were formed in the membrane due to the dissolution of mannitol and sucrose nanoparticles 
in the membrane structure and the diameter of pores (600-700 nm) are close to the size of sucrose and 
mannitol nanoparticles in the coating suspension shown in Figure 1.  SEM images of F24 (blank SPM, 
Figure 2c) showed no pores which could be due to the absence of pore former in the formation. Figure 2c 
also shows that the system contains lots of crack at the surface of the device after the dissolution which 
could be because of a high internal osmotic pressure arising from the swelling of the polymer in the core 
of tablet leading to the formation of cracks in SPM. The presence of cracks led to the system expulsion in 
less than one hour leading to dose dumping which will be discussed in the relevant section below. These 
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images were comparable to those reported in previous articles for CPOP systems formulated with other 
commonly used pore formers [26, 27, 28]. 
 
2.4 Effect of core formulation and pore former concentration on drug release 
Drug release profiles of 4-amino pyridine from osmotic formulations containing different concentrations 
of sucrose as a pore former (F1 to F4) in the coating liquid were shown in Figure 3a. According to this 
Figure, by increasing pore former concentration from 1% (F4) to 8% (F1), drug release rate increased 
during the first 120 min. Drug release rate from all mentioned formulations were faster than the desired 
rate probably due to a higher internal pressure. This high pressure may also be responsible to system 
cracking as described before. These formulations cracked in the first two hours due to the high amount 
(50 mg) of polymer which caused high swelling pressure after the exposure to the dissolution medium. 
These formulations also had higher osmotic pressure due to the higher content of the osmotic agent 
(sucrose) in their central cores.     
An attempt was made to reduce the concentration of sucrose (an osmotic agent) from 175 mg to 100 mg 
in the core (F5-F9) to reduce the internal osmotic pressure and hence the drug release. At the same time, 
talc was also incorporated in the formulations as a neutral filler to maintain the tablet weights in the 
range. The results showed that the percentage drug release reduced (compare Figures 3a and 3b) by 
decreasing the osmotic agent (sucrose) in the core formulation. This may be described as lower amount 
of sucrose in core tablet formulation created lower osmotic pressure gradient leading to the lower water 
imbibing rate into the system and consequently causing the decreased drug release.  
As shown in figure 4, decreasing of osmotic agent from 175 mg to 100 mg caused a significant 
improvement in stability of the system against cracking (4 to 6 hours). Among F5 –F9, the formulations 
with lower amounts of pore former in their SPMs (F8 and F9 with 0.5 and 0.1% pore former) showed 




Figure 4a demonstrates how by reducing the amount of HPMC in the core almost a similar release pattern 
can be obtained, although they have different concentrations of pore former (F10 and F11). Decreasing 
HPMC level from 50 mg to 20 mg in the core (F10-F11) caused an improvement in SPM resistance until 
8 hours but all above formulations are not suitable for 12 h drug delivery because they lost their integrity 
during the dissolution run after a few hours. The appearance of the cracks in these systems are most likely 
due to the higher polymer swelling force leading to low resistance of SPM as these cracks can also be 
seen in formulations with less osmotic agent. But reducing the polymer amount in core tablets to 10 mg or 
elimination of the polymer resulted in very robust SPM. In addition, systems with lower or higher 
concentrations of sucrose (less than 2% or more than 6%) in their SPM formulation showed faster 
cracking in the tablets. It seems that higher percent of pore former in SPM, disintegrates the structure of 
SPM and lower percent of pore former disable to provide sufficient pores to relief the internal hydrostatic 
pressure leading to low SPM resistance and therefore cracking. 
 
Figures 4b and 5 demonstrate the release profiles of F12-F16 (containing 10 mg HPMC in the core) and 
F18-F22 (without HPMC in the core). Formulations F12-F16 also contain different concentrations of pore 
former (0.1-4%). It seems that less resistance of SPM of F14 is related to the insufficient pores to 
evacuate the internal hydrostatic pressure. The better stability of F12 in comparison with F10 revealed 
that the amount of osmotic agent was the same (100 mg) and the only variable was the amount of polymer 
(20 and 10 mg for F10 and F12 respectively) which could be an important factor for resistance of the 
system during the dissolution process. With decreasing the polymer concentration in the core formulation, 
swelling force of polymer decreases and stability of the SPM against internal pressure of the system 
improves. This observation also indicates that the polymer swelling force probably was responsible for 
cracking of F10 and F11. 
Among formulations F12–F16, F15 exhibited good characteristics such as acceptable D12h (more than 
75% drug release) and closest to zero order release pattern in comparison to the other formulations 
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(RSQzero = 0.99). The presence of HPMC in core formulations and formation of gel containing drug may 
result in low D12h value in F13and F14 which contained higher amount of pore former (1.5 and 1% 
respectively). 
Formulations F18-F22 (Figure 5) were prepared with no HPMC in their core tablets with pore-former 
concentration of 4-0.1% respectively. In this group of formulations, the internal hydrostatic pressure was 
in minimum level compared to others and thus, all of them maintained their integrity during 12h and F22 
with 0.1% pore former demonstrated lowest release rate (5.77 mg/h) and D12 (69.26%). Optimum 
formulations were selected for evaluation of mannitol as pore-former (F17 and F23). Based on Figure 6, 
the data revealed that mannitol can also act as a pore-former. The comparative parameters of selected 
(resistant devices against cracking) formulations are illustrated in Table 2. The most important advantage 
of all optimized formulations using this novel nano-suspension coating is having negative lag time. This 
means that the drug release starts as soon as the device contacts with the dissolution medium which is a 
big advantage over other osmotic devices. The nano sized hydrophilic pore formers were able to dissolve 
immediately after the exposure to the aqueous media and produce pores for drug release during the first 
couple of minutes.  
Although most of the coated tablets cracked, it is highly unlikely cracking can occur in the tablets 
over the period of time if the relative humidity is controlled. In case of storing these tablets on the 
shelf at very high relative humidity (e.g. 98%) if the tablet absorbs moisture from the environment 
there is a chance that tablets might crack.  
Nowadays, porous materials are becoming more popular in tablet systems such as mesoporous 
silicon particles [29] as they can improve the dissolution of hydrophobic drugs and also enhance the 
permeability of large hydrophobic molecules [30]. Although, in the present study, the application of 
porous materials on the performance of osmotic pumps was not investigated, the authors suggest 
that it is important to compare the effect of inorganic porous materials in coating system with 





The applicable and effectiveness of the nano-suspension coating technique with glycosides in formulation 
of CPOP systems was verified by this study. The most essential parameters in these formulations were the 
amount of pore former in the membrane and gelling agent in the core formulation to achieve durable 
device. The most important achievement for the osmotic system using nano-suspension coating is the 
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Figure 2. SEM images of (a) mannitol, (b) sucrose containing SPM and (c) blank (SPM without 

























Figure 3. Release profiles of (a) F1-F4 containing different amounts of pore former in SPM, 175 
mg osmotic agent and 50 mg HPMC; (b) F5-F9 containing different amounts of pore former in 
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Figure 4. Release profiles of (a) F10-F11 containing different amounts of pore former in SPM 
and 20mg HPMC in core formulation; (b) F12-F16 containing different amounts of pore former 
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Figure 5. Release profiles of F18-F22 containing different amounts of pore former in SPM and 










































Figure 6. Release profiles of F17 and F23 with different amounts of HPMC in core formulation 




Table 1. Core and SPM composition of different formulations (all formulations contained 20 mg 4-Amino pyridine 
in core and 6% w/v cellulose acetate 3% w/v castor oil and 2% w/v PEG200 in SPM). 
Formulation 
     Code  
                  Core Composition     SPM Composition 




F1 50 150 175 90 - 8 - 
F2 50 150 175 90 - 4 - 
F3 50 150 175 90 - 2 - 
F4 50 150 100 90 - 1 - 
F5 50 150 100 90 75 8 - 
F6 50 150 100 90 75 4 - 
F7 50 150 100 90 75 2 - 
F8 50 150 100 90 75 1 - 
F9 50 150 100 90 75 0.5 - 
F10 20 150 100 90 105 4  
F11 20 150 100 90 105 1 - 
F12 10 150 100 90 115 4  
F13 10 150 100 90 115 1.5 - 
F14 10 150 100 90 115 1 - 
F15 10 150 100 90 115 0.5 - 
F16 10 150 100 90 115 0.1 - 
F17 10 150 100 90 115 - 0.5 
F18 0 150 100 90 125 4 - 
F19 0 150 100 90 125 1.5 - 
F20 0 150 100 90  1 - 
F21 0 150 100 90 125 0.5 - 
F22 0 150 100 90 125 0.1 - 
F23 0 150 100 90 125 - 0.5 

















F13 0.98 73.19 -0.02 0.15 6.10 
F14 0.99 72.29 -0.06 14.70 6.02 
F15 0.99 80.37 -0.08 9.24 6.70 
F19 0.99 72.58 -0.16 37.89 6.05 
F20 0.98 82.23 -0.07 14.5 6.85 
F21 0.99 80.33 -0.08 0.13 6.69 
F22 0.97 69.26 0.39 0.75 5.77 
F23 0.99 72.58 0.14 0.21 6.05 
F17 0.97 71.26 -0.11 49.93 5.94 
 
